My ePortfolio Register   

A rationale for early intervention in ER+ metastatic breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.09.16
Views: 3510

Dr Hope Rugo - University of San Francisco Cancer Research Institute, San Francisco, USA

If cancer cells remain after initial treatment, they have a greater likelihood of developing resistance later on in the disease. Using the most effective treatment from the start may help decrease the risk of treatment
resistant cancer cells in the future (Pfizer sponsored).

Visit to find out more about the global state of metastatic breast cancer and to learn
about the impact of breast cancer on women, please visit

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence